EETs/sEH in diabetes and obesity-induced cardiovascular diseases
- 1 September 2016
- journal article
- review article
- Published by Elsevier BV in Prostaglandins & Other Lipid Mediators
- Vol. 125, 80-89
- https://doi.org/10.1016/j.prostaglandins.2016.05.004
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular diseaseAtherosclerosis, 2012
- Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistanceProceedings of the National Academy of Sciences of the United States of America, 2011
- Obesity, insulin resistance and free fatty acidsCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension‐induced renal injury in miceThe FASEB Journal, 2010
- Inhibition or Deletion of Soluble Epoxide Hydrolase Prevents Hyperglycemia, Promotes Insulin Secretion, and Reduces Islet ApoptosisThe Journal of pharmacology and experimental therapeutics, 2010
- Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseasesNature Reviews Drug Discovery, 2009
- Epoxyeicosatrienoic Acid Agonist Rescues the Metabolic Syndrome Phenotype of HO-2-Null MiceThe Journal of pharmacology and experimental therapeutics, 2009
- Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivoMolecular Cancer Therapeutics, 2009
- Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolaseCell Biology and Toxicology, 2008
- Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolaseBioorganic & Medicinal Chemistry Letters, 2006